Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May-Jun;3(3):256-68.
doi: 10.1002/wnan.123. Epub 2011 Jan 31.

Microfabrication and nanotechnology in stent design

Affiliations
Review

Microfabrication and nanotechnology in stent design

Adam W Martinez et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 May-Jun.

Abstract

Intravascular stents were first introduced in the 1980s as an adjunct to primary angioplasty for management of early complications, including arterial dissection, or treatment of an inadequate technical outcome due to early elastic recoil of the atherosclerotic lesion. Despite the beneficial effects of stenting, persistent high rates of restenosis motivated the design of drug-eluting stents for delivery of agents to limit the proliferative and other inflammatory responses within the vascular wall that contribute to the development of a restenotic lesion. These strategies have yielded a significant reduction in the incidence of restenosis, but challenges remain, including incomplete repair of the endothelium at the site of vascular wall injury that may be associated with a late risk of thrombosis. A failure of vessel wall healing has been attributed primarily to the use of polymeric stent coatings, but the effects of the eluted drug and other material properties or design features of the stent cannot be excluded. Improvements in stent microfabrication, as well as the introduction of alternative materials may help to address those limitations that inhibit stent performance. This review describes the application of novel microfabrication processes and the evolution of new nanotechnologies that hold significant promise in eliminating existing shortcomings of current stent platforms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A number of laser specific variables, including intensity, wavelength, and pulse length, as well as material ablation formats are selected with respect to specific material properties for optimal stent fabrication.
Figure 2
Figure 2
Example of two laser machined bioabsorbable stents. The top stent is courtestsy Laser Zentrum Hannover(© Laser Zentrum Hannover e.V. (LZH)) and the bottom stent is courtesy of Resonetics(©Resonetics)
Figure 3
Figure 3
The difference between femtosecond laser pulses and nanosecond pulses on thin steel films. The SEM image on the left shows a hole drilled in a 100μm thick steel foil with 200 fs, 120 μJ, F = 0.5J/cm2 laser pulses at 780nm. The SEM image on the right shows the molten material left behind when holes were drilled in a 100μm thick steel foil with 3.3 ns, 1 mJ, F = 4.2J/cm2 laser pulses at 780nm.(©Springer-Verlag 1996 ) (115)
Figure 4
Figure 4
Micro- and nano- fabrication has facilitated the design stents that harbor reservoirs for local drug delivery. (A) A single strut of a bare metal stent expanded in the vessel pressed against the endothelium with the smooth muscle cells beyond the endothelium. (B) Drug containing polymer coated strut and represents the first generation of drug eluting stents. Newer strategies include the incorporation of (C) microtopographic features that provide increased surface area for drug loading, (D) lumen-oriented reservoirs, and (E) drug reservoirs that extend throughout the strut structure.
Figure 5
Figure 5
The Cordis NEVO™ stents has reservoirs machined into the stent struts(Courtesy of Cordis Corporation)
Figure 6
Figure 6
Surface Modifications strategies to enhance endothelialization include: (A) surface roughening to increase topography, (B) discreet patterning, (C) chemical modification of the surface, and (D) covalent attachment of biopharmaceuticals.
Figure 7
Figure 7
Scanning Electron Microscope images at different magnifications of the expanded Translumina YUKON®DES Coronary Stent System with PEARL surface coated with leflunomide. The microporous stent surface allows for the incorporation of drugs with slower release kinetics without the need for a polymer coating. The roughness of the stent surface is 1.96±0.21 μm(Reprinted with permission of the Elsevier Ireland Ltd. © 2008) (116)
Figure 8
Figure 8
Illustrates the magnetic targeting of bovine aortic endothelial cells(BAECs) under flow conditions to stainless-steel stents in vitro and in vivo. Magnetically responsive BAECS are shown captured on SS stents based on (A) red fluorescence of the MNPs and (B) Calcein staining of live cells. To determine in vivo capture BAECs were loaded with fluorescent MNPs and injected into the ventricular cavity. (C) Rats were exposed to a magnetic field of 1,000 G for 5 minutes then sacrificed and the stents were removed and imaged. (D) Control rats were not exposed to magnetic field. (© 2008 The National Academy of Sciences of the USA) (113)

Similar articles

Cited by

References

    1. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. American Heart Journal. 2006;151(6):1260–4. - PubMed
    1. Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007 Nov 20;116(21):2391–8. - PubMed
    1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193–202. - PubMed
    1. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 Feb 27;115(8):1051–8. - PubMed
    1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998–1008. - PubMed

LinkOut - more resources